Clinical Trials Logo
  1. Home
  2. Nicotine Dependence
  3. NCT04170907

Pharmacokinetics and Pharmacodynamics of Different Nicotine Salt Concentration Vape System Pods and Free-base Nicotine

Nicotine Dependence Clinical Trial

Official title:
Randomized Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Two Different Nicotine Salt Concentrations and Free-base Nicotine Using an Open Vape Pod System

Clinical Trial Summary

Comparison of the pharmacokinetics and pharmacodynamics of two different nicotine salt concentrations and free-base nicotine using an open vape pod system

Clinical Trial Description

On each study day, one puff will be taken with the assigned product every 30 seconds (total of 10 puffs). Blood samples will be collected to measure nicotine 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff using the modified Minnesota Nicotine Withdrawal Scale (MNWS), the Tiffany Questionnaire on Smoking Urges (QSU), and the Positive and Negative Affect Schedule (PANAS) questionnaires. Respiratory symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects of the assigned product (e.g. satisfying, calming, pleasant, vape another one right now) will also be assessed using visual analog scales. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04170907
Study type Interventional
Source University Hospital Inselspital, Berne
Contact
Status Completed
Phase N/A
Start date April 19, 2022
Completion date August 30, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05176418 - IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate Early Phase 1
Completed NCT04084210 - Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use Phase 2
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Withdrawn NCT03707600 - State and Trait Mediated Response to TMS in Substance Use Disorder N/A
Recruiting NCT03999099 - Targeting Orexin to Treat Nicotine Dependence Phase 1
Completed NCT03847155 - Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery N/A
Completed NCT02840435 - Study on Sit to Quit Phone Intervention N/A
Completed NCT02139930 - Project 2: Strategies for Reducing Nicotine Content in Cigarettes N/A
Completed NCT01982110 - A Mindfulness Based Application for Smoking Cessation N/A
Completed NCT01926626 - Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers Phase 2
Withdrawn NCT01569477 - Striving to Quit-Wisconsin Tobacco Quit Line N/A
Completed NCT01685996 - Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation Phase 1/Phase 2
Completed NCT01632189 - The Effect of Varenicline on D2/D3 Receptor Binding in Smokers N/A
Completed NCT01569490 - Striving to Quit: First Breath N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT00996034 - Nicotine Vaccination and Nicotinic Receptor Occupancy Phase 2
Completed NCT01061528 - Coping Skills Treatment for Smoking Cessation N/A
Withdrawn NCT01589081 - Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect N/A
Completed NCT01943994 - Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study N/A
Suspended NCT01636336 - Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects N/A